{"entity":{"id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","aka":[],"tldr":"A phase 3 trial of Imlunestrant, Tamoxifen and Exemestane in advanced solid tumours, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer is a phase 3 interventional study registered as NCT05514054 by Eli Lilly and Company, with 8000 participants enrolled, started 2022-10-04 and due to reach its primary completion in 2027-10. Interventions recorded: Imlunestrant, Tamoxifen, Anastrozole, Letrozole and Exemestane.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05514054","url":"https://clinicaltrials.gov/study/NCT05514054"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["imlunestrant","tamoxifen","exemestane"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05514054","phase":"3","setting":"EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence","sponsor":"Eli Lilly and Company","enrolled":8000,"outcomes":[]},"route":"/trials/nct05514054/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}